Afecta Pharmaceuticals Granted New US Patent for Neuro-Immuno Modulators
Why this matters
Commercial real estate continues to digest a multi-year reset in cost of capital. Transaction velocity is below the 2019-2021 trend but improving, cap rates have stabilized across most stabilized property types, and the bid-ask gap has narrowed materially in the past two quarters. Sponsors with permanent capital and operating platforms have an advantage in the current execution environment. The next twelve months will continue to reward underwriting discipline and operational sophistication over balance-sheet aggression.
Editorial analysis · Real Estate Trail Editorial
IRVINE, Calif., Aug. 25, 2026 /PRNewswire/ -- Afecta Pharmaceuticals, focused on developing breakthrough multi-target therapies for complex disorders announced that USPTO has granted the company a new patent entitled…
External link. Real Estate Trail does not republish source content.
More from the wire
TransUnion, Equifax debut ‘score later’ tools for mortgage lenders
New workflows let lenders pull credit files without scores and add them later
Senior housing wealth tops $15 trillion for the first time
The milestone comes as borrowing costs remain elevated